Figure S2 from Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8⁺ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

<p>Tumor infiltrating lymphocytes (TIL) were isolated 5 days post adoptive transfer according to the materials and methods section. Cells were gated for Thy1.2 expression. <b>A)</b> Galectin-3 wildtype (WT) high avidity CD8⁺ T cells were adoptively transferred into either galectin-3 WT (red) or galectin-3 KO neu-N (blue) recipient mice. Histogram overlays show differences in galectin-3 MFI between the two groups with respect to isotype control staining (orange). <b>B)</b> Galectin-3 staining is now shown on galectin-3 KO high avidity CD8⁺ T cells adoptively transferred into a galectin-3 KO neu-N recipient (blue) with respect to an isotype control (red). <b>C)</b> TCR avidity is compared between galectin-3 WT high avidity CD8⁺ T cells from a galectin-3 WT neu-N recipient and galectin-3 KO high avidity CD8⁺ T cells from a galectin-3 KO neu-N recipient. TCR avidity was assessed by staining with a 1:100 dilution of MHC I Dq tetramer loaded with the RNEU420-429 (P50) peptide. This experiment was repeated twice with similar results. <b>D)</b> Histogram overlays demonstrating differences in surface galectin-3 MFI on adoptively transferred high avidity tumor specific CD8⁺ T cells (Thy1.2⁺) vs. endogenous CD8⁺ T cells in the tumor microenvironment (Thy1.2^-)</p>